Taxotere Articles
GPC presents promising data at AACR
10 April 2006
Sanofi-Aventis sales slow on competition
6 February 2006
SD Pharma completes preclinical study on novel docetaxel form
16 January 2006
Sanofi's Taxotere gets priority review for advanced gastric cancer
12 December 2005
Progen expands PI-88 development to prostate cancer
15 August 2005
Sanofi-Aventis: is growth slowing?
1 August 2005
Canadian provinces OK Genentech's Herceptin
1 August 2005
Strong 2nd qtr for Sanofi-Aventis
25 July 2005
Cell Thera's Xyotax sees strong Ph III results
18 July 2005
Cell Genesys starts second Ph III GVAX trial
18 July 2005
Stock Commentary - Europe
13 June 2005
Stock Commentary - New York
23 May 2005
Positive results on PharmaMar's Yondelis
23 May 2005
Tapestry sees preclinical promise in taxane candidate
28 April 2005
PT's lead candidate shows antitumor effect
26 April 2005
GPC Biotech's Satraplatin on track
25 April 2005
Roche's Xeloda gains EU OK for colon cancer
11 April 2005
Novogen granted fast-track status
28 February 2005
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
Phenoxodiol boosts efficacy of Taxotere
31 January 2005
Taxotere cleared for two new indications
17 January 2005
Sanofi-Aventis scoops marketing awards
20 December 2004
EC clears Sanofi-Aventis' Taxotere for prostate cancer
8 November 2004
Innovative drugs and their impact on the future of oncology developments
20 September 2004
New NSCLC trial for AstraZeneca's Iressa
20 September 2004
Roche's Xeloda filed for new indication
30 August 2004
FDA OKs 2nd indication for Lilly's Alimta
30 August 2004
Aventis Taxotere gets OK for new use by FDA
23 August 2004
Cell Genesys' CG7870 starts combi trial
23 August 2004
Thalomid effective in prostate cancer
12 July 2004
New use in EU for Roche's Herceptin
28 June 2004
ILEX' ILX-651 starts prostate cancer trial
28 June 2004
Velcade data for MM and NSCLC at ASCO
21 June 2004
OSI's Aptosyn fails in Phase III NSCLC study
21 June 2004
FDA OKs Aventis' Taxotere for prostate cancer
24 May 2004
Aventis' sales grow 7.1% but Allegra falls
3 May 2004
New use for Aventis' Taxotere in Japan
26 January 2004
Stock Commentary - Europe
15 December 2003
Aventis disposes of Behring unit with $925M sale to Australia's CSL
15 December 2003
Aventis' Taxotere shows promise in early-stage breast cancer, filings expected 2004
15 December 2003
New data for Taxotere in the MBC setting
6 October 2003
Herceptin combi helps breast cancer survival
6 October 2003
Aventis on target as performance picks up
4 August 2003
Aventis' Taxotere and cisplatin improve QoL
28 July 2003
Promising new data for Lilly's Alimta
28 July 2003
Alimta has fewer side effects than Taxotere
16 June 2003
Cytogen's Quadramet efficacy in tumors
16 June 2003
NY claims of Rx overcharging could lead to industry-wide probe
24 February 2003
Aventis to sell Seripharm
17 February 2003
OSI to acquire Cell Pathways for $32M
17 February 2003
Taxotere cleared in EU as first-line NSCLC drug
20 January 2003
Vitamin D boosts Taxotere efficacy in prostate cancer
6 January 2003
Aventis reports positive gastric cancer results
8 July 2002
FDA turns down early Casodex use
1 July 2002
Taxol vs Taxotere trial finds tox advantage
3 June 2002
Taxotere boosts survival in breast cancer
27 May 2002
Alimta: first effective mesothelioma drug
27 May 2002
Aventis blockbusters driving growth
6 May 2002
Roche's Xeloda in Ph III as first-line agent
11 March 2002
FDA approves Amgen's new-generation filgrastim product, Neulasta
11 February 2002
Antisoma drug boosts activity of taxanes
28 January 2002
Aventis growth driven by strong US pharmaceutical sales
6 November 2001
Viral drug promising in prostate cancer
26 October 2001
Update: Roche cancer drugs backed by CPMP
24 October 2001
Chugai in $73M deal with Cell Therapeutics
23 October 2001
CPMP recommends Xeloda for breast cancer
22 October 2001
Aventis still confident about hitting 35% earnings rise for 2001
27 September 2001
New NICE guidance on Fludara in CLL; breast cancer advice on taxanes to
25 September 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
